600062 华润双鹤
已收盘 10-23 15:00:00
资讯
新帖
简况
华润双鹤：10月21日组织现场参观活动，上海证券交易所、投资者等多家机构参与
证券之星 · 10-23 19:03
华润双鹤：10月21日组织现场参观活动，上海证券交易所、投资者等多家机构参与
股市必读：华润双鹤新发布《华润双鹤关于全资子公司北京万辉双鹤药业有限责任公司巴瑞替尼片获得药品注册证书的公告》
证券之星 · 10-22
股市必读：华润双鹤新发布《华润双鹤关于全资子公司北京万辉双鹤药业有限责任公司巴瑞替尼片获得药品注册证书的公告》
股市必读：华润双鹤新发布《华润双鹤关于全资子公司安徽双鹤药业有限责任公司复合磷酸氢钾注射液获得药品注册证书的公告》
证券之星 · 10-21
股市必读：华润双鹤新发布《华润双鹤关于全资子公司安徽双鹤药业有限责任公司复合磷酸氢钾注射液获得药品注册证书的公告》
华润双鹤(600062.SH)子公司复合磷酸氢钾注射液获药品注册证书
智通财经 · 10-19
华润双鹤(600062.SH)子公司复合磷酸氢钾注射液获药品注册证书
股市必读：华润双鹤新发布《华润双鹤关于全资子公司双鹤药业（海南）有限责任公司注射用吗替麦考酚酯通过仿制药质量和疗效一致性评价的公告》
证券之星 · 10-19
股市必读：华润双鹤新发布《华润双鹤关于全资子公司双鹤药业（海南）有限责任公司注射用吗替麦考酚酯通过仿制药质量和疗效一致性评价的公告》
华润双鹤（600062）披露全资子公司注射用吗替麦考酚酯通过一致性评价公告，10月15日股价下跌1.03%
证券之星 · 10-15
华润双鹤（600062）披露全资子公司注射用吗替麦考酚酯通过一致性评价公告，10月15日股价下跌1.03%
华润双鹤（600062）10月14日主力资金净买入300.14万元
证券之星 · 10-15
华润双鹤（600062）10月14日主力资金净买入300.14万元
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司氢溴酸伏硫西汀原料药获得化学原料药上市申请批准通知书的公告》
证券之星 · 10-12
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司氢溴酸伏硫西汀原料药获得化学原料药上市申请批准通知书的公告》
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》
证券之星 · 09-30
股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》
华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价
证券之星 · 09-23
华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价
华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书
证券之星 · 09-14
华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书
每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批
证券之星 · 09-13
每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批
华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%
证券之星 · 09-09
华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%
华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书
智通财经 · 09-08
华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
证券之星 · 09-06
每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书
股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》
证券之星 · 09-03
股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》
华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%
证券之星 · 09-01
华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%
华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书
智通财经 · 08-31
华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书
华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具
证券之星 · 08-31
华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具
股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》
证券之星 · 08-31
股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》
加载更多
公司概况
公司名称：
华润双鹤药业股份有限公司
所属行业：
医药制造业
上市日期：
1997-05-22
主营业务：
华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、肝素钠、依诺肝素原料。
发行价格：
6.69
{"stockData":{"symbol":"600062","market":"SH","secType":"STK","nameCN":"华润双鹤","latestPrice":16,"timestamp":1792738800000,"preClose":15.93,"halted":0,"volume":7840464,"delay":0,"changeRate":0.0044,"floatShares":1038000000,"shares":1039000000,"eps":1.5577,"marketStatus":"已收盘","change":0.07,"latestTime":"10-23 15:00:00","open":15.9,"high":16.06,"low":15.7,"amount":125000000,"amplitude":0.0226,"askPrice":16,"askSize":66,"bidPrice":15.99,"bidSize":38,"shortable":0,"etf":0,"ttmEps":1.5577,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":5,"adr":0,"adjPreClose":15.93,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":17.52,"lowLimit":14.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1038572452,"isCdr":false,"pbRate":1.36,"roa":"--","peRate":10.271554,"roe":"7.68%","epsLYR":1.5949,"committee":0.147014,"marketValue":16617000000,"turnoverRate":0.0076,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-26。","floatMarketCap":16612000000},"requestUrl":"/m/hq/s/600062/","defaultTab":"news","newsList":[{"id":"2677262239","title":"华润双鹤：10月21日组织现场参观活动，上海证券交易所、投资者等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2677262239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677262239?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:03","pubTimestamp":1792753427,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年10月23日华润双鹤发布公告称公司于2026年10月21日组织现场参观活动，上海证券交易所、投资者 、南方基金、中信建投证券、国寿养老、中金财富参与。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300037539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0010","600062","BK0175","BK0028","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677601330","title":"股市必读：华润双鹤新发布《华润双鹤关于全资子公司北京万辉双鹤药业有限责任公司巴瑞替尼片获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677601330","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677601330?lang=zh_cn&edition=full","pubTime":"2026-10-22 03:06","pubTimestamp":1792609574,"startTime":"0","endTime":"0","summary":"截至2026年10月21日收盘，华润双鹤报收于16.11元，下跌0.92%，换手率0.49%，成交量5.06万手，成交额8193.99万元。公司公告汇总华润双鹤关于全资子公司北京万辉双鹤药业有限责任公司巴瑞替尼片获得药品注册证书的公告华润双鹤全资子公司万辉双鹤近日获得国家药监局颁发的巴瑞替尼片《药品注册证书》，规格为2mg，注册分类为化学药品4类，视同通过一致性评价。目前国内已有9家企业获批该药品，2025年国内销售总额为4.25亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600062","BK0028","BK0175","BK0188","BK0239","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677188536","title":"股市必读：华润双鹤新发布《华润双鹤关于全资子公司安徽双鹤药业有限责任公司复合磷酸氢钾注射液获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677188536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677188536?lang=zh_cn&edition=full","pubTime":"2026-10-21 01:13","pubTimestamp":1792516388,"startTime":"0","endTime":"0","summary":"华润双鹤关于全资子公司北京万辉双鹤药业有限责任公司巴瑞替尼片获得药品注册证书的公告华润双鹤全资子公司万辉双鹤近日获得国家药监局颁发的巴瑞替尼片《药品注册证书》，规格为2mg，注册分类为化学药品4类，视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100001432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0239","BK0185","600062","BK0028","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676504388","title":"华润双鹤(600062.SH)子公司复合磷酸氢钾注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2676504388","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676504388?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:26","pubTimestamp":1792401989,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司全资子公司安徽双鹤药业有限责任公司收到了国家药品监督管理局颁发的复合磷酸氢钾注射液《药品注册证书》。复合磷酸氢钾注射液作为磷补充剂：1.当口服或肠内营养无法进行、不足或有禁忌时，用于纠正成人和儿童患者的低磷血症。2.当口服或肠内营养无法进行、不足或有禁忌时，用于成人和儿童患者的肠外营养。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1508908.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0010","BK0028","BK0188","BK0175","BK0185","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676737305","title":"股市必读：华润双鹤新发布《华润双鹤关于全资子公司双鹤药业（海南）有限责任公司注射用吗替麦考酚酯通过仿制药质量和疗效一致性评价的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2676737305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676737305?lang=zh_cn&edition=full","pubTime":"2026-10-19 04:06","pubTimestamp":1792353975,"startTime":"0","endTime":"0","summary":"公司公告汇总：华润双鹤全资子公司海南双鹤注射用吗替麦考酚酯通过仿制药质量和疗效一致性评价，该药品2025年国内终端市场销售额6,618万元，海南双鹤市场份额达97.74%。该药品适用于预防肾移植或肝移植患者的急性器官排斥反应。截至公告日，公司累计研发投入290.30万元。国内已有8家企业获批上市该药品，其中5家通过或视同通过一致性评价。该药品由外部单位负责销售，存在合同履约不确定性风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900001274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0185","BK0010","BK0028","600062","BK0175","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675853336","title":"华润双鹤（600062）披露全资子公司注射用吗替麦考酚酯通过一致性评价公告，10月15日股价下跌1.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675853336","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675853336?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:15","pubTimestamp":1792073722,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘，华润双鹤报收于16.34元，较前一交易日下跌1.03%，最新总市值为169.7亿元。公告显示，公司全资子公司海南双鹤收到国家药监局颁发的注射用吗替麦考酚酯《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。截至公告日，公司累计研发投入290.30万元。国内已有8家企业获批上市该药品，其中5家通过或视同通过一致性评价。2025年国内终端市场销售额为6,618万元，海南双鹤市场份额达97.74%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500039369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0175","BK0188","600062","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675375622","title":"华润双鹤（600062）10月14日主力资金净买入300.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675375622","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675375622?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:20","pubTimestamp":1792023616,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月14日收盘，华润双鹤报收于16.51元，上涨1.41%，换手率0.86%，成交量8.95万手，成交额1.47亿元。近5日资金流向一览见下表：华润双鹤融资融券信息显示，融资方面，当日融资买入815.62万元，融资偿还1236.33万元，融资净偿还420.71万元。华润双鹤主营业务：慢病业务、专科业务和输液业务三大业务平台。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500006913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","600062","BK0185","BK0188","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845550","title":"股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司氢溴酸伏硫西汀原料药获得化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845550","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845550?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:59","pubTimestamp":1791741548,"startTime":"0","endTime":"0","summary":"公司公告汇总：控股子公司氢溴酸伏硫西汀原料药获国家药监局上市批准，累计研发投入948.91万元。该原料药用于治疗成人抑郁症，双鹤湘中此前已获批氢溴酸伏硫西汀片剂。华润双鹤关于全资子公司北京双鹤润创科技有限公司DC7001A胶囊获得美国FDA临床试验许可的公告华润双鹤全资子公司北京双鹤润创科技有限公司研发的DC7001A胶囊已获美国FDA同意开展临床试验，该药品拟用于治疗系统性红斑狼疮，此前已获得中国国家药品监督管理局的临床试验批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0185","BK0028","BK0188","BK0010","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671265244","title":"股市必读：华润双鹤新发布《华润双鹤关于控股子公司华润双鹤湘中药业(湖南)有限公司布瑞哌唑原料药获得化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671265244","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671265244?lang=zh_cn&edition=full","pubTime":"2026-09-30 03:16","pubTimestamp":1790709374,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，华润双鹤报收于15.92元，下跌0.38%，换手率0.37%，成交量3.8万手，成交额6053.05万元。当日关注点交易信息汇总：9月29日游资资金净流入610.85万元，占总成交额10.09%，为当日主力资金流向中最显著项。公司公告汇总：控股子公司华润双鹤湘中药业布瑞哌唑原料药获国家药监局批准注册，适用于治疗成人精神分裂症，累计研发投入969.87万元。双鹤湘中于2025年3月7日提交申请，2026年9月21日获批，在CDE原辅包登记平台状态为“A”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002986.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","600062","BK0239","BK0188","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669104682","title":"华润双鹤最新公告：子公司盐酸普萘洛尔注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2669104682","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669104682?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:29","pubTimestamp":1790155742,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司华润紫竹药业收到国家药监局颁发的盐酸普萘洛尔注射液《药品补充申请批准通知书》，批准增加2ml:2mg规格，该药品通过仿制药质量和疗效一致性评价。该药品适用于控制室上性快速心律失常、劳力型心绞痛等。截至公告日，公司累计研发投入333.84万元。2025年该药品销售收入306.22万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300029726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0185","BK0010","BK0239","BK0188","BK0028","600062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654139","title":"华润双鹤最新公告：全资子公司依折麦布阿托伐他汀钙片获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654139","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667654139?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:27","pubTimestamp":1789378071,"startTime":"0","endTime":"0","summary":"华润双鹤(600062.SH)公告称，公司全资子公司华润赛科收到国家药监局颁发的依折麦布阿托伐他汀钙片(含Ⅰ、Ⅱ两种规格)《药品注册证书》，视同通过一致性评价。该药品适用于高胆固醇血症和纯合子型家族性高胆固醇血症的治疗。截至公告日，公司累计研发投入2036.37万元。本次获批将进一步丰富公司产品线，提升市场竞争力。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400022576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0175","BK0010","BK0188","BK0028","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667070425","title":"每周股票复盘：华润双鹤（600062）复方葡萄糖/电解质冲洗液获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667070425","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667070425?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:55","pubTimestamp":1789239309,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，华润双鹤报收于15.83元，较上周的16.02元下跌1.19%。本周，华润双鹤9月9日盘中最高价报16.31元。华润双鹤当前最新总市值164.41亿元，在化学制药板块市值排名26/149，在两市A股市值排名1151/5218。公司于2023年6月启动研发，2024年12月提交上市申请，2026年9月获批，累计研发投入1,324.62万元。该产品视同通过一致性评价。目前国内已有4家企业获批，2025年国内市场规模为6万元。该药品上市将丰富公司产品线，提升市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0175","600062","BK0188","BK0028","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666581125","title":"华润双鹤（600062）披露复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书，9月9日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666581125","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666581125?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:38","pubTimestamp":1788946738,"startTime":"0","endTime":"0","summary":"截至2026年9月9日收盘，华润双鹤报收于16.21元，较前一交易日上涨0.06%，最新总市值为168.35亿元。该股当日开盘16.21元，最高16.31元，最低16.09元，成交额达7379.88万元，换手率为0.44%。华润双鹤药业股份有限公司近日收到国家药品监督管理局颁发的复方葡萄糖/电解质颅脑手术冲洗液《药品注册证书》，该药品为化学药品3类，适用于颅脑手术、脊髓疾病手术及神经内镜手术时的洗净与灌流。该药品上市将丰富公司产品线，提升市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900030214.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","600062","BK0185","BK0188","BK0010","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326372","title":"华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326372","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326372?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:06","pubTimestamp":1788858414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司收到了国家药品监督管理局颁发的复方葡萄糖/电解质颅脑手术冲洗液《药品注册证书》。该药品适用于颅骨钻孔、开颅手术时的洗净、脊髓疾病手术时的洗净及神经内镜手术时的灌流。此次获得《药品注册证书》视同通过一致性评价。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华润双鹤(600062.SH)：复方葡萄糖/电解质颅脑手术冲洗液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0010","600062","BK0175","BK0028","BK0185","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366853","title":"每周股票复盘：华润双鹤（600062）奥卡西平片获注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366853","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366853?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:54","pubTimestamp":1788634452,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，华润双鹤报收于16.02元，较上周的16.16元下跌0.87%。公司公告汇总华润双鹤控股子公司华润双鹤湘中药业(湖南)有限公司近日收到国家药监局颁发的奥卡西平片《药品注册证书》，视同通过一致性评价。华润双鹤药业股份有限公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0175","BK0028","BK0185","BK0010","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664845165","title":"股市必读：华润双鹤新发布《华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664845165","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664845165?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:10","pubTimestamp":1788372623,"startTime":"0","endTime":"0","summary":"公司公告汇总：华润双鹤获得洛莫司汀胶囊《药品注册证书》，为化学药品5.1类，规格40mg，获批时间2026年8月25日，获6年数据保护期。公司公告汇总华润双鹤关于洛莫司汀胶囊获得药品注册证书的公告华润双鹤药业股份有限公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。截至公告日，累计研发投入222.98万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0010","BK0239","BK0028","BK0188","600062","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857025","title":"华润双鹤（600062）披露洛莫司汀胶囊获得药品注册证书公告，9月1日股价上涨0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857025","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857025?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:57","pubTimestamp":1788274631,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，华润双鹤报收于16.09元，较前一交易日上涨0.06%，最新总市值为167.11亿元。该股当日开盘16.02元，最高16.14元，最低15.97元，成交额达9819.78万元，换手率为0.59%。华润双鹤近日发布关于洛莫司汀胶囊获得药品注册证书的公告。公告显示，公司近日获得国家药监局颁发的洛莫司汀胶囊《药品注册证书》，该药品为化学药品5.1类，规格为40mg，适用于经手术和/或放疗后的原发性恶性脑肿瘤患者。截至公告日，累计研发投入222.98万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0175","BK0028","BK0239","BK0188","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076587","title":"华润双鹤(600062.SH)子公司奥卡西平片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076587","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663076587?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:02","pubTimestamp":1788166955,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，近日，公司控股子公司华润双鹤湘中药业(湖南)有限公司收到了国家药品监督管理局颁发的奥卡西平片《药品注册证书》。奥卡西平片适用于治疗成年人和5岁及以上儿童的原发性全面性强直-阵挛发作和部分性发作，伴有或不伴有继发性全面性发作。此次获得《药品注册证书》视同通过一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","BK0188","600062","BK0175","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078741","title":"华润双鹤：积极研究运用股份回购、大股东增持、股权激励等市值管理工具","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078741","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663078741?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:36","pubTimestamp":1788161810,"startTime":"0","endTime":"0","summary":"证券之星消息，华润双鹤(600062)08月31日在投资者关系平台上答复投资者关心的问题。投资者提问：资金在哪里？股票跌跌不休华润双鹤回复：感谢您对公司的关注！二级市场股价受宏观环境、行业政策、资金偏好等多重因素综合影响，具有不确定性。公司将结合财务状况、发展战略等综合因素，积极研究运用股份回购、大股东增持、股权激励等市值管理工具，促进公司整体市值实现持续、健康提升。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100015876.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","600062","BK0185","BK0028","BK0239","BK0010","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663047024","title":"股市必读：华润双鹤新发布《华润双鹤关于重大资产重组的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2663047024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663047024?lang=zh_cn&edition=full","pubTime":"2026-08-31 06:26","pubTimestamp":1788128771,"startTime":"0","endTime":"0","summary":"公司公告汇总：华润双鹤拟以现金方式收购利尔化学23.50%股份，构成重大资产重组，目前正推进尽职调查、审计及评估工作。公司公告汇总华润双鹤关于重大资产重组的进展公告华润双鹤药业股份有限公司拟以支付现金方式购买四川久远投资控股集团有限公司、四川化材科技有限公司合计持有的利尔化学股份有限公司188,102,749股股份，占其总股本的23.50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100001611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600062","BK0239","BK0028","BK0175","BK0188","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792941302116,"stockEarnings":[{"period":"1week","weight":-0.0226},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0157},{"period":"6month","weight":-0.085},{"period":"1year","weight":-0.1358},{"period":"ytd","weight":-0.105}],"compareEarnings":[{"period":"1week","weight":-0.0069},{"period":"1month","weight":-0.0625},{"period":"3month","weight":-0.0324},{"period":"6month","weight":-0.0954},{"period":"1year","weight":-0.0591},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润双鹤药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"52736人(较上一季度减少4.07%)","perCapita":"19687股","listingDate":"1997-05-22","address":"北京市朝阳区望京利泽东二路1号","registeredCapital":"103857万元","survey":" 华润双鹤药业股份有限公司的主营业务是慢病业务、专科业务、输液业务。公司的主要产品是缬沙坦、氨氯地平、普瑞巴林、氨苯蝶啶、喷他佐辛、匹伐他汀、肝素钠、依诺肝素原料。","listedPrice":6.69},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华润双鹤,600062,华润双鹤股票,华润双鹤股票老虎,华润双鹤股票老虎国际,华润双鹤行情,华润双鹤股票行情,华润双鹤股价,华润双鹤股市,华润双鹤股票价格,华润双鹤股票交易,华润双鹤股票购买,华润双鹤股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华润双鹤(600062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华润双鹤(600062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}